Appili COVID Trial Expands to Mexico, Brazil

Halifax-based Appili Therapeutics, a biopharmaceutical company developing drugs for infectious diseases, has added clinical research sites in Mexico and Brazil to its Phase 3 clinical trial evaluating favipiravir as a potential oral therapy for patients with mild-to-moderate COVID-19.
The expansion into Mexico and Brazil will ensure a timely completion of the trial, the company said in a